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Abstract
Background: High-throughput measurement technologies such as microarrays provide complex datasets reflecting
mechanisms perturbed in an experiment, typically a treatment vs. control design. Analysis of these information rich
data can be guided based on a priori knowledge, such as networks or set of related proteins or genes. Among those,
cause-and-effect network models are becoming increasingly popular and more than eighty such models, describing
processes involved in cell proliferation, cell fate, cell stress, and inflammation have already been published. A
meaningful systems toxicology approach to study the response of a cell system, or organism, exposed to bio-active
substances requires a quantitative measure of dose-response at network level, to go beyond the differential
expression of single genes.
Results: We developed a method that quantifies network response in an interpretable manner. It fully exploits the
(signed graph) structure of cause-and-effect networks models to integrate and mine transcriptomics measurements.
The presented approach also enables the extraction of network-based signatures for predicting a phenotype of
interest. The obtained signatures are coherent with the underlying network perturbation and can lead to more robust
predictions across independent studies. The value of the various components of our mathematically coherent
approach is substantiated using several in vivo and in vitro transcriptomics datasets. As a proof-of-principle, our
methodology was applied to unravel mechanisms related to the efficacy of a specific anti-inflammatory drug in
patients suffering from ulcerative colitis. A plausible mechanistic explanation of the unequal efficacy of the drug is
provided. Moreover, by utilizing the underlying mechanisms, an accurate and robust network-based diagnosis was
built to predict the response to the treatment.
Conclusion: The presented framework efficiently integrates transcriptomics data and “cause and effect” network
models to enable a mathematically coherent framework from quantitative impact assessment and data interpretation
to patient stratification for diagnosis purposes.
Keywords: Systems biology, Causal network model, Transcriptomics data
Background
High-throughput measurement technologies provide
comprehensive data sets to obtain insight on disease
mechanisms and the biological impact of exposure to
active substances, such as drugs and environmental
toxicants. However, the scientific community faces an
ongoing challenge to analyze and interpret these data sets
and derive useful insights about the studied biological
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systems. The analysis of high-throughput expression data
typically leads to a list of differentially expressed genes.
However, this approach often fails to provide mechanis-
tic insights into the underlying biology. During recent
years, researchers addressed the complexity of such data
by evaluating them in a relevant biological context [1],
whereby genes are grouped based on a priori knowl-
edge such as MSigDB [2]. Sets of genes are then used by
algorithms determining their specificity (or enrichment)
in a particular experiment [3]. Kathri et al. [1] recently
reviewed and categorized them into three main successive
© 2014 Martin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
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generations: over-representation analysis (ORA), func-
tional class scoring (FCS) and pathway topology (PT).
Unlike ORA approaches that only consider differentially
expressed genes, FCS approaches, such as GSEA [2], take
into account the entire dataset without applying thresh-
olds. The development of PT approaches was motivated
by the increasing evidence that interactions between
genes or proteins better describe underlying molecular
mechanisms [4]. These approaches allowed for a better
use of pathway and network collections, such as KEGG,
BioCarta, MIPS [5], the Database of Interacting Proteins
(DIP) [6], and theMolecular Interaction database (MINT)
[7]. The mapping of genes onto pathway or network
representations has resulted in algorithms with better
specificity because they account for the topology of the
pathway or network [1,8]. Nevertheless, most currently
available pathway tools rely on the “forward assumption”,
where protein activity changes are assumed to be directly
correlated with expression changes of their coding genes
[9,10]. This assumption does not always hold [11-13];
furthermore calculations that are based on few genes may
lack robustness. Table 1 shows some representative of
methodologies relying on this assumption, and their key
features.
In contrast, the “backward assumption” groups together
the genes which have been described in the literature to
be regulated by a given molecular entity, referred as to the
upstream biological entity (UBE) (Figure 1b). UBEs are as
diverse as transcription factors (as in [19] or [20]), protein
activities, complexes or bioactive chemical compounds.
Relationships between a givenUBE and its regulated genes
additionally include the sign (inhibition or activation) of
the regulation. Such signed gene sets are also called HYPs,
standing for “Hypotheses”, as described in [21]. Signed
gene sets are leveraged by methodologies such as Reverse
Causal Reasoning [21], modified GSA [22], by the net-
work perturbation approach [23] (Table 1). UBEs can be
further assembled into networks (Figure 1a), whereby an
edge between two entities represents a cause-and-effect
relationship, typically an activation or an inhibition. Net-
work nodes may also include entities that are not known
to regulate any genes. Thus, these network models have a
two-layer structure, as shown in Figure 1a, where the func-
tional level (the UBEs, called the backbone, in orange) is
explicitly distinguished from the transcriptional level (the
genes, in black). Recently, an ensemble ofmore than eighty
such networkmodels that consist of cause-and-effect rela-
tionships between molecular entities and activities (e.g.
kinase activation or increased protein abundance) have
been published [24-27] and made available to the commu-
nity for peer-review [28]. The description of the biological
context has been manually built into the network models
using prior knowledge extracted from both relevant liter-
ature and published datasets after a large-scale knowledge
mining effort [21]. These networks describe biological
processes such as cell proliferation, cell apoptosis and
senescence, cell stress, and inflammation. Further bio-
logical processes can be described using cause-and-effect
relationships from the OpenBEL framework [29]. Open-
BEL is an open platform technology designed to collect
cause-and-effect statements that can be further assembled
into two-layer networks.
To assess qualitatively the enrichment of such networks,
one could leverage the results of any (signed) gene set
method testing the significance of the UBE’s in the net-
work and subsequently test the over-representation of the
significant ones by a hypergeometric or binomial test.
Under the backward paradigm, such a method would
correspond to an ORA approach (Table 1) with the lim-
itations discussed in [1], such as applying thresholds and
ignoring inter-relationships between the entities in the
network. In order to score a two-layer network, the entire
network can be collapsed into a single signed gene set and
an FCS approach that can handle signs (Table 1) can be
applied. Martin et al. [23] followed this approach, using
uniquely defined signs between entities in the network
and a fixed reference node. This approach accounts only
for a spanning tree of the network and disregards the rest
of the topology, hence does not classify as a PT approach
as such (Table 1). In a “proof-of-principle” study, using this
method, we have quantified the perturbation of a given
UBE based on high-throughput data [23] and showed that
it correlates with independent assay endpoint. However,
the applicability of the method is restricted to causally
consistent networks (e.g., no negative feedback loops are
allowed), and does not allow for the identification of the
key drivers of the network perturbation. Identifying the
key mechanisms responsible for the activation or pertur-
bation of a network/gene set is a valuable feature of any
methodology, leveraging either the forward or the back-
ward assumption. For example, GSEA approaches extract
the leading-genes of a scored gene set to serve as the
basis for further interpretation. However many methods
(including [23]) do not provide such a layer for interpreta-
tion (Table 1).
Gene expression data have being used to derive diag-
nostic signatures that inform clinicians on disease states
or treatment outcomes. Majority of research has involved
identifying and scoring signatures that are correlated with
a disease phenotype [30,31]. Due to the high number of
genes that aremeasured with high signal to noise ratio and
genotypic variability across individuals, gene-level signa-
tures often lack consistency between independent studies.
Signatures may also lack biological meaning and inter-
pretability because they are often derived from machine
learning approaches that do not include a priori knowl-
edge. A number of studies have shown that network



















Table 1 Classification of the different methodologies and some of their representatives (see [1,14] for more exhaustive lists)
Reasoning Category Method Qualitative Quantitative Use topology Interpretability Diagnostic Sigs Threshold-free
Forward











































√ √ √ √ √ √
For each represented method, their properties are described. The method described in this study, TopoNPA, is to our knowledge the first backward PT methodology. ORA: Over-Representation Analysis, FCS: Functional Class
Scoring, PT: Pathway Topology. (
√
): with small modification.
































2. Explanation: backbone scoring and 









3. Diagnostic: functional features
Figure 1 Our methodology for quantifying the perturbations of biological networks provides a coherent framework for multifaceted
results. a) Biological network model: the functional layer, or the backbone, is shown in orange, whereas the transcriptional layer is shown in black.
Each causal edge is directed and signed. A given gene can be modulated by several nodes of the backbone model as depicted by several black
arrows linking several nodes of the functional layer to a single node of the transcriptional layer. b) The fundamental paradigm shift between forward
and backward reasoning; while the former considers the gene transcript abundance as a direct surrogate for its associated protein (or protein
function), the latter considers the changes in gene transcription as the consequence of the activity of the upstream biological entity described by a
node in the functional layer. c) Our new methodology provides a coherent framework connecting Network Perturbation Amplitude quantification
(top panel), with mechanistic explanations and identification of the leading nodes in a network (middle panel) and finally the extraction of
functional features (i.e., biomarkers) which can be used to stratify patient populations (bottom panel, points are individual samples in the new
feature space and colors indicate a different phenotype).
pathways or protein-protein interaction networks were
used as substrates to derive predictive signatures [32-38].
The objective of this research was to establish a compu-
tational methodology that can integrate gene expression
data with a two-layer cause-and-effect network by using
its full topology to identify, interpret and quantify the per-
turbation of the network in response to any treatment.
The quantification of the network perturbation (and its
significance) extends the concept of differential expres-
sion of single genes to the pathways or networks [8]
and is of value in fields of toxicology and pharmacol-
ogy [39], where dose and time response are studied. This
approach goes beyond the enrichment approaches used
in many pathway/network tools, which are focused on
testing a non-enrichment null hypothesis [1,22,40]. The
quantification of the network perturbation in response to
a treatment enables not only a comparison across sev-
eral networks, but also a comparison between several
treatments on the same network [41]. First, we applied
our method to datasets and networks to compare the
results qualitatively and quantitatively with the expected
outcomes, as well as the results obtained when using
other computational approaches. Second, based on one
additional dataset derived from a controlled experiment
involving the cell cycle, we showed that the key drivers
identified by our method are aligned with the expected
biology. Third, two additional public datasets were used
to quantify the xenobiotic metabolism response to smoke
exposure, identify the key drivers and derive a robust
smoking exposure signature. The performance of our
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network-based signature was compared to several recog-
nized computational approaches. Finally, we applied our
methodology to study the mechanisms underlying the
unequal efficacy of an anti-inflammatory drug in patients
suffering from ulcerative colitis and provide a plausible
mechanistic hypothesis. Utilizing the underlying mech-
anisms, an accurate and robust network signature for
predicting individual patient responses was generated.




The data used in this study were either obtained
from internal experiments that are described hereafter
(Additional file 1) or downloaded from the public repos-
itories such as Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/) or ArrayExpress (http://www.ebi.
ac.uk/arrayexpress/) (see Table 2). Raw RNA expres-
sion data were analyzed using the affy and gcrma
packages of the Bioconductor suite of microarray anal-
ysis tools available in the R statistical environment
(version 2.14.0). Robust Microarray Analysis (RMA) back-
ground correction and quantile normalization were used
to generate probe set expression values. The fold-changes
and their moderated t-statistics were computed using
limma [42].
Network models
Networks models are a representation of the relation-
ships between the biological activities taking place in the
considered cellular systems. They are based on infor-
mation extracted manually from the scientific literature
and encoded in the BEL syntax. BEL is a computable
format for unambiguously capturing biological entities
and their inter-relationships and associating them with
external vocabularies and ontologies [29]. The nodes of
the networks correspond to molecular biological enti-
ties (e.g., protein abundances, protein activities, chemical
compounds and gene expression) and also include cellular
processes (e.g., apoptosis). The network edges connect
two nodes and represent the cause-and-effect relation-
ship between the corresponding entities (e.g., the tran-
scriptional activity of NFKB directly increases the gene
expression of BCL2). Edges are directed as a consequence
of their causal nature. They are additionally signed, indi-
cating whether the changes (increase or decrease) of the
connected nodes have same (→) or opposite () signs. An
ensemble of more than eighty such network models are
made available at [28].
In the “backward-causal” paradigm, the changes in the
activities of molecular biological processes, the UBE’s,
can be inferred based on the changes measured for their
causally “downstream” entities, in our case the differen-
tial expression of the genes causally affected by considered
processes. For example, the activity of CYP1A1 is not
measured but its change, between a treated and untreated
condition, is reflected in the expression of the genes
described to be altered by it (Figure 1a). Another example
is the change in the activity of a transcription factor which
is deduced from the changes in the expression of its direct
targets, and not from the changes in the expression of
its mRNA. This paradigm is becoming increasingly pop-
ular [21,23,43,44] and among others, “backward-causal”
features have been introduced recently in Ingenuity Path-
way Analysis software [43]. Using RNAi experimental
data, Markowetz et al. showed that upstream path-
way relationships between unobserved molecular entities
can be reliably deduced from downstream measurable
entities [45].
This is in contrast to the “forward-causal” approach,
where the activity changes of a protein is approximated by
the differential expression of its corresponding transcript
(see Figure 1a). The number of “downstream” of a typical
UBE is between a dozen and several hundreds. Additional
details can be found in the Additional file 1.
In a nutshell, our networks models are made of signed
gene sets (empty or not) related by signed directed edges.
By definition of the two-layer structure there are no edges
between genes in the transcript layer as we assume here
Table 2 Overview of the datasets used
Data ID Tissue Treatment
GSE7895 Bronchial Brushing Smokers (30), non-smokers (20), former smokers (51)
GSE19667 Bronchial Brushing Smokers (65), non-smokers (45)
GSE12251 & GSE1480 Colonic biopsies Responders (20) and non-responders (27) pre-treatment
GSE16879 Colonic biopsies Responders (8) and non-responders (16) pre-/post-treatment
E-MTAB-1842, GSE50254 Rat parenchyma Main stream smoke (8, 15, or 23 μg nicotine/l) or fresh air. 5 animals per group.
E-MTAB-1272 NHBE cells 2 , 4, 6 and 8 hours after washing of CDK4/6 inhibitor. 3 samples per group.
E-MTAB-1311 NRBE cells Vehicle control or TNFα (0.1, 1, 10, 100 ng/ml) × (30 min, 2 h, 24 h). 3 samples per group
GSE identifiers refer to datasets in Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and E-MTAB identifiers to dataset deposited in ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/). The number of samples per group is indicated in parenthesis.
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that relationships between genes are driven by the func-
tional layer. An overview of network models used in this
study is given in Table 3. One can observe that the size of
the functional layer (a few dozen to hundred) is small as
compared to the size of the transcript layer (several thou-
sands of genes). The networkmodels used in this study are
further discussed in Additional file 1 and are available in
the Additional file 2.
The topological network perturbation amplitude scoring:
TopoNPA
Our method aims at reducing the high dimensional
transcriptomics data by combining the gene expression
(log2)fold-changes into fewer differential backbone values
(between a few dozen and two hundred). By definition of
the two-layer structure, no measurements corresponding
to nodes in the functional layer are available. The differ-
ential backbone values will be therefore determined by a
fitting procedure that infers values that best satisfy the
directional and signed relationships contained in the back-
bone model (Figure 1a, orange nodes and edges), while
being constrained by the experimental data (the gene log2-
fold-changes, β) (Figure 1a, black nodes). An overview of
the steps involved in the methodology is summarized in
Figure 2.
Objective and problem statement
Let G = (V ,E, σ) be the signed directed graph underlying
the biological network (whereV is the set of vertices, E the
set of edges, and σ : E → {+1,−1} is the sign function)
and let us assume that G is strongly connected. The set
of nodes of the transcript layer is denoted by V0 and its
complement, the backbone, by V \ V0.
For each negatively signed edge, x  y (e.g., between the
kinase activities of AKT2 and MAPK14, kaof (AKT2) 
kaof (MAPK14)), we assume that an additive change of
α ∈ R in the value of x results in a change of−w(A,B)·α in
the value of ywherew(x, y) > 0 is a weight associated with
the edge. Similarly for positive relationships, a change of
α ∈ R in the value x results in a change of w(x, y) · α in
the value of y. In the absence of further information, the
weights are assumed to be 1 as in many network-based
approaches (e.g., [35,46]).
If the network model was perfectly representing the
data, one could expect the values on V , denoted by f ∈
l2(V )a, to satisfy all the “cause and effect” statements of
the network model and, on V0, to equal the computed
fold-changes. Hence, being given the vector of (log2-) fold-
changes β ∈ l2(V0) for the genes in the transcript layer,
the optimal fit of the network to the data is computed as
the “smoothest” (in the sense of graph regularization [47])
vector f ∈ l2(V ) such that its restriction (denoted by |.) to
the transcript layer is equal to the observed fold-changes






f (x) − sign(x → y)f (y))2 w(x, y)
such that f |V0 = β ,
where w(x, y) is the weight associated with the edge
bounded by x and y. This problem relates directly to a
Dirichlet boundary condition problem in spectral graph
theory [48].
Due to the fact that some biological entities of the back-
bone are more studied than others in the literature, UBE’s
with a lot of downstream genes (edges to the transcrip-
tional layer) will have a very high degree in the graph,
as compared other nodes in the backbone. To overcome
this issue, the weights associated with the edges x → y
from a backbone node to its nx downstream in the tran-
scriptional layer (if existing) will be set to w(x, y) = 1nx .
Equivalently, all the genes have the same importance in
describing the UBE’s and therefore the out degree to the
transcript layer of any UBE will be 1. This adjustment will
value the backbone structure, which is intended to capture
the biology and balances the importance of the backbone
and the transcript layer (the latter being by far bigger than
the former, see Table 3).
Solution of the constrained optimization
For x ∈ v let out(x) (resp in(x)) be the weighted out (resp.
in)-degree of the vertex x. Leveraging the quadratic nature
of the problem, one can show that it is equivalent to:
minf∈l2(V ) f T
(





such that f |V0 = β
Table 3 Statistics for the networks used in this study
#Nodes #Edges #Nodes with downstream #Genes involved
TNF-IL1α-TLR-NFκB (Hs) 116 237 50 3874
TNF-IL1α-TLR-NFκB (Rn) 116 237 50 3874
Cell Cycle (Hs) 127 240 57 8059
Xenobiotic metabolism (Rn) 31 49 20 2668
Xenobiotic metabolism (Hs) 34 53 21 2781
The network edges and nodes can be found in the Additional file 2.
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Figure 2 TopoNPA workflow takes as input gene log2-fold changes and a fixed network structure. a) The measured gene log2-fold changes
are used to infer the differential backbone values for which no direct measurements are available. This step relies on the backward assumption. The
differential values obtained on the backbone are summarized in a single number quantifying how strong they are and how well those values agree
with the signed graph structure of the backbone. b) Once the perturbation is quantified, three statistics are computed to assess the significance of
TopoNPA with respect to the experimental error and its specificity to the given two-layer network structure.




sign(x → y) · w(x, y) if x → y
0 else
Even though the problem involves the directed edges
only, the quadratic nature of the objective function leads
to symmetric matrices and involves the matrix L =
diag(out)+diag(in)−(A+AT ), which is the signed Lapla-
cian of the undirected graph; hence the directionality of
the edges has no more importance at this stage.
Let L3 denote the sub-matrix of L whose rows and
columns consist of the backbone nodes, and L2 the sub-
matrix whose rows correspond to the backbone nodes and
columns to the genes in the transcript layer. A straight-
forward differentiation with respect to f of the expression
above and using the constraint shows that the solution is
given by
f |V\V0 = −L−13 LT2 β
As L3 is weakly diagonal dominant and strictly diag-
onal dominant for at least one row (as the transcript
layer is assumed to be non-empty) and as the underly-
ing undirected backbone graph is assumed to be strongly
connected, L3 is irreducibly diagonally dominant. There-
fore, it will be non-singular, ensuring the existence and
uniqueness of the solution.
Laplacian and related matrices, like the diffusion ker-
nel on graphs, have been successfully used to prioritize
disease genes or to assess pathway enrichment (see e.g.,
[46,49,50]) where the added value for accounting for the
full network topology is demonstrated. Unlike thesemeth-
ods, where the data are mapped directly on a graph,
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the problem solved here involves an additional boundary
constraint as the smoothing is applied to the backbone
network only.
Quantifying the perturbation
The objective is to summarize into a single number,
called Network Perturbation Amplitude, how well and
how strongly the inferred values match with the net-
work, with the aim to capture dose and time response
of the network, typically in toxicological testing. If all
the inferred differential backbone values are high and
all the signed edges in the backbone are accommodated
by those values (i.e., the objective function for the solu-
tion is low), the highest should be the perturbation of
the network. Also, as the optimization problem is con-
strained, the differential backbone values can be relatively
high, but still not accommodating well the edge signs.
Based on this intuition, we concluded that the pertur-
bation should be a function of the edges and not the
nodes alone. Additionally, we should avoid canceling out
(“destructive interference”) cumulative signed edge scores
(for example when a network with all positive edges con-
tains two subgraphs linked by a single edge, one with all
positive values and the other with negative values, one
could have a vanishing score while a single edge may be
wrong). This situation, where subnetwork perturbations
and network perturbation are inconsistent, could typically
happen in [23]. Hence, our choice was to consider an
“energy” (e.g., quadratic) analogue quantity for each edge.
Therefore, the network perturbation amplitude is calcu-
lated using the differential backbone values, f |V\V0 and is
defined as a positive number representing the cumulated
“energy” of f |V\V0 ; i.e., each edge x → y contributes to(
f (x) + sign(x → y)f (y))2. This score will be consistent
with the objective function minimized.
Formally this is defined by the Sobolev (semi-) norm on
the graph (V ,E,−σ), normalized by the number of edges







f (x) + sign(x → y)f (y))2
· w(x, y)(∗)
Unless explicitly stated, w(x, y) = 1 for all the edges of
the backbone. Following the argument above, this expres-
sion is a quadratic form 1C · f |TV\V0Qf |V\V0 , where Q ∈












This first step is described in Figure 2a.
Vanishing of the TopoNPA score
Let G−b = (Vb,Eb, σb) be the signed subgraph induced by
V\V0 (the backbone) and for which the sign function is
defined by σb = −σ |Eb . The signed Laplacian of G−b is
exactly Q. It follows directly from the Rayleigh quotients
that the TopoNPA score is bounded by
0 ≤ || f |V\V0 ||
2
C λ1
(G−b ) ≤ TopoNPA(G,β)




where λ1 (Gb) (respectively λn
(G−b )) is the smallest
(respectively, largest) eigenvalue of Q.
Let us focus on the vanishing of λ1
(G−b ). By defini-
tion, a graph is balanced if and only if all its cycles are
positive. This property is called “causally consistent” in
[23]. Equivalently, G−b is balanced if there exists a parti-
tion V = V1 ∪ V2 such that every edge between V1 and
V2 is negative and every edge within V1 or V2 is positive
[51]. It follows from the Matrix-Tree theorem for signed
graph, that λ1
(G−b ) = 0 if and only if G−b is balanced [51].
This implies in this case that the kernel of Q is exactly the
subspace of constant functions f ≡ c on V1 and f ≡ −c
on V2, for any real c. As a formal consequence, if (and
only if ) the graph is balanced, a TopoNPA score can be
zero while the backbone values are piecewise constant as
described above; which rarely occurs due to the boundary
constraint. The steps involved in building the TopoNPA
score are depicted in Figure 2a.
Confidence intervals
In order to derive confidence intervals for the differen-
tial backbone values and the TopoNPA score, we show
that the covariance between the gene (log2-)fold-changes
β (which is not the same as the covariance between the
genes) vanishes under a weak assumption. Let (X,Y )
be a pair of random variables describing two genes and
let us assume that ((X,Y )|Untreated, (X,Y )|Treated) .=(
XU ,YU ,XT ,YT
) ∼ N ((μU ,μT ) ,UT ). The covariance
between the fold-changes, where we have m1 (respec-
tively, m2) i.i.d. samples in the treated (respectively,

























































Thus, assuming that there is no second order effect of
the treatment (or equivalently homoscedasticity between
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) = Cov (XU ,YT) = Cov (XT ,YU)),
the above expression vanishes. Consequently, under
this assumption, β ∼ N (μT − μU , diag(var(βi)));
which leads to the variance-covariance matrix of
the backbone differential values var(−L−13 LT2 β) =




. As a consequence, the
variance of a TopoNPA score can be computed as
var(hTQh) = 2tr(Q2Q2) + 4μT2 Q2Qμ2 (where





Asymptotically correct confidence intervals are then
derived using the central limit theorem (Figure 2b).
The companion statistics
Although a TopoNPA score can be highly significant with
respect to the biological variation (lower limit of its con-
fidence interval above zero), it does not imply that the
gene fold-changes specifically reflect the network struc-
ture itself. In order to assess this aspect, two complemen-
tary permutation statistics are introduced: the “O” and
the “K”-statistics. The ability to distinguish the specifically
perturbed networks from the non-specific ones is key as a
total of 89 sub-networks have been built to date and can be
used simultaneously. These companion statistics quantify
the relevance of the information contained in the network
model in determining the score (Figure 2b).
“O” The first one assesses the adequacy of the
downstream genes assignment (transcript layer) to
the nodes of the backbone model by reshuffling the
gene labels in the transcript layer. It tests the null
hypothesis that the position of the genes in the
transcript layer has no importance in defining the
score. Therefore gene labels are permuted and the
TopoNPA score is recomputed. This procedure is
repeated B times (usually B = 500) and a
permutation p-value is derived.
“K” The second statistic assesses the importance of the
cause-and-effect relationships encoded in the
backbone of the network in extracting the TopoNPA
scores. It tests the null hypothesis that the structure
of the backbone has no importance in deriving the
TopoNPA score. The edges of the functional layer
are randomly permuted (together with their signs),
differential backbone values are re-computed and
TopoNPA is recomputed using the original matrix Q.
This procedure is repeated B (usually B = 500) times
and a permutation p-value is derived.
The upper bound value on (∗∗) states that the highest
possible value for the TopoNPA (for unit norm functions)
is achieved by the eigenvectors for the largest eigenval-
ues of G−b , which in spectral theory are called the high
energy function on the graph. As the highest eigenvalue
λn
(G−b ) is invariant under the permutations described
above, the two statistics can be interpreted as testing if the
smoothest function on Gb satisfying the constraints given
by the experimental data is also a high l2-norm function
and a high energy function (as compared to other ran-
dom configurations of the network) on G−b . Subsequently,
the network is considered to be specifically perturbed if
both p-values are low (usually 0.05). The TopoNPA results
will always be interpreted in light of the three companion
statistics: the two permutation p-values and its confidence
interval.
The leading nodes
To ease the interpretation of a significant perturbation,
the major contributors in the sum (∗) can be identified. By
sorting the terms inTopoNPA = 1C
∑
x∈V\V0(Qf |V\V0)(x)·
f |V\V0(x), one compute the contribution of any node y as
100 · 1C (Qf |V\V0 )(y)·f |V\V0 (y)TopoNPA and rank those accordingly.
The key contributors to the perturbation, referred to
as leading nodes (Figure 1c, middle panel) are by def-
inition the nodes that make up 80% of the TopoNPA
score. It both accounts for the differential backbone values
themselves but also to the centrality of the nodes in the
functional layer.While 80% is an empirical choice, we have
observed that it is usually a promising start to interpret
the perturbation and does not preclude, if for example all
the contributions are almost equal, to use further ranked
nodes. As demonstrated in the next section, the notion
of leading nodes is a very useful way to interpret the per-
turbation; an appropriate understanding of the perturbed
biology can only be achieved if the topology of the net-
work and the differential values of the network nodes are
equally taken into account.
Deriving network signatures
As differential backbone values are obtained through a
linear transformation of the fold-changes, individual gene
expression profiles can be transformed into backbone val-
ues that can subsequently be used for the purpose of
classification. For single samples, gene expression profiles
are centered, leading to a differential value between the
individual profile and the population average. So to map
the individual sample data X (genes x samples matrix) to
the backbone, we simply compute B = −L−13 LT2 X. This
new data matrix will serve as the basis for the classifica-
tion tasks. As this linear transform does not depend on
the data, cross-validation schemes can be performed on
the transformed data B. The linearity of this transforma-
tion ensures that the differential backbone values obtained
from the fold-changes are the same as the difference
of the average backbone values of the individual map-
pings. The latter property is important for the coherence
of the TopoNPA framework. This step of the method-
ology depicted in Figure 1c, bottom panel, where points
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represent samples, colors code for different phenotypes
and axes illustrate the backbone nodes.
Comparison to quantification/enrichmentmethods
Comparing gene set/pathway analysis methods in a real
experiment is not straightforward because no quantitative
performance metrics (like e.g., ROC, Sensitivity, Speci-
ficity) are applicable as the “ground truth” is unknown.
However, the methods can be compared based on how
well their results fit with the existing biological knowl-
edge. This type of assessment is the current best practice
in this area [2]. In each use-case, two aspects will be com-
pared to the expected biology: the presence or absence of
an enrichment, based on the significance (qualitative) and
the dose(/time)-response patterns (quantitative).
As our method is developed with the aim to exploit the
specific two-layer structure of cause-and-effect networks,
it was compared to the results of methodologies using
the same structure, obtained by straightforward adapta-
tions of existing approaches. Those ones belong to three
categories [1]:
Forward FCS approaches: Gene-set enrichments
methodologies are applied to the set of genes in the
transcript layer. Following [22], several combinations
of gene-level statistics and gene set enrichment
statistics are used. For the gene-level statistics,
moderated-t statistics and fold-changes are
considered; the former being the canonical choice in
FCS enrichment approaches and the latter being the
statistics used in TopoNPA. For the enrichment
statistics (denoted ES, in Additional file 1: Figure S1
and S3), we used the mean, maxmean [52], and
GSEA [2].
Backward ORA approaches: A straightforward
approach to test the enrichment of a two-layer
network model is to test the enrichment of each
UBE in the functional layer by RCR [21], which is
specifically designed for UBE’s and subsequently test
the enrichment of the network by a hypergeometric
test. The overall “perturbation” is defined as −log10
(p − value).
Backward FCS approaches: Another approach is to
test the enrichment of each UBE in the functional
layer (as a signed gene set, by multiplying each gene
statistics by the sign of the edge from the UBE to the
gene) and subsequently test the enrichment of the
significant UBE’s by a hypergeometric test. To
quantify the perturbation of the functional layer one
simply considered the sum of squared enrichment
scores of the UBE’s (denoted SS(ES) in Additional
file 1: Figure S2 and S4). To test the enrichment of
UBE’s, the same combinations of gene-level statistics
and enrichment statistics described above were used.
The results were also compared to our previous
methodology, NPA [23].
Comparison to signaturemethods
The comparison between feature selection (i.e., extracting
a subset of genes) and feature construction was the main
aspect considered. Hence the performance across differ-
ent machine learning methods (for a fixed set of features)
was not the main focus of this work.
Our results were compared to the classification per-
formances of the following computational methods. The
first method, not using any of the network information,
was the method of the winning team of the IMPROVER
Diagnostic Signature Challenge [53,54], referred to as,
tForwardLd. The first step of the method is to order the
features by absolute values of the associated moderated
t-statistics. In a second step, the predictors are used one
after the other in a LDA model based on this ordering
(i.e., LDA based on the first predictor, the two first, three
first and so on). At each step an internal cross-validation is
computed and the final set of features is selected accord-
ingly. The selection step of this method is included within
the cross-validation instances performed in the compari-
son study to avoid any selection bias in the performance
assessment. This methodology was applied on the full
set of genes and on the genes in the transcript layer
only.
As highlighted in [53] as a take home message of the
SBV IMPROVER Diagnostic Signature Challenge, the
choice of the base classifier should not impact the predic-
tion performance as much as the choice (either selection
or construction) of the features. This observation has led
us to choose Linear Discriminant Analysis (LDA), lin-
ear support vector machine (SVM), random forests (RF)
[55] and, Nearest Shrunken Centroids (NSC) [56] as the
base classifiers. In every instance, NSC algorithm cross-
validation results were obtained by selecting the shrinking
parameter by an internal cross-validation within each
cross-validation step.
A more sophisticated methodology, the COndition
Responsive Genes (CORG) approach [34] using the UBE’s
was also compared. In this approach, one new feature for
each UBE is constructed and a classifier is applied on the
resulted set of features. Again, the feature construction
step is included within each cross-validation step as it
depends on the training data.
Finally, LDA or NSC prediction models derived from
the genes underlying each UBE individually was build and
the best one (based on the cross-validated G-performance
(which is the geometric mean between sensitivity and
specificity)) was reported.
The extraction of the differential backbone values for
individual samples is a purely unsupervised computation
and only involves a fixed linear transform of the data





. Therefore, the cross-validation for classifiers
based on the backbones values is equivalent to the cross-
validation on the original samples for the combination of
the mapping to the backbone values and the classifier. All
cross-validations are 10-fold cross-validation, averaged
over 5 repetitions.
Results
TopoNPA distinguishes specific from irrelevant
perturbations and enables dose-response calculations
We first evaluated the ability of TopoNPA to capture
quantitatively a network perturbation and the companion
statistics to distinguish specific from irrelevant pertur-
bations. For that purpose, networks and datasets were
chosen where clear biological expectations were available.
Those biological expectations will serve as the basis for
comparing TopoNPA to other methods.
Description of the data and networks
The xenobiotic metabolism network is part of the cell
stress model, representing the response to external stres-
sors for non-diseased tissue with a focus on the pul-
monary and cardiovascular systems [24]. Representing
an unrelated mechanism, the TNF-IL1α-TLR-NFκB net-
work model, including the toll-like receptors (TLRs),
interleukin-1A (IL1A) and tumor necrosis factor-α (TNF)
arms, covers the major signaling pathways that lead
to Nuclear Factor-κB (NFκB) activation in response to
inflammation [57].
The first dataset (E-MTAB-1842, GSE50254) was
derived from a 28-day cigarette smoke inhalation exper-
iment conducted in rats and was expected to show
perturbation in both networks, because cigarette smoke
is a known inducer of inflammation and xenobiotic
metabolism in the rat respiratory tract [58]. We have also
used a second dataset (E-MTAB-1311) from rat large air-
way progenitor cells (RLAK) treated with increasing doses
of TNF for 0.5, 2, and 24 hours.
In the first experiment, a dose response of the TNF-
IL1α-TLR-NFκB network activation was expected [59].
Similarly, the activation of the xenobiotic metabolism
response network was expected to follow a dose response
pattern [58]. In the second experiment, the TNF response
was monitored by measuring the nuclear translocation of
NFκB after treatment at 0.5 hours (data not shown) and
led to expect a significant network perturbation amplitude
evolving in a dose and time dependent manner. Finally,
no xenobiotic metabolism response was expected in this
second experiment. The comparison of the results will be
performed based on those biological expectations.
Comparison to other quantification/enrichmentmethods
The perturbation of the TNF-IL1α-TLR-NFκB network
was evident in the rat lung parenchyma when the rats
were exposed to smoke as compared to the sham-treated
animals (Figure 3a). Similarly, the network was activated
in TNF treated RLAK cells in a dose and time depen-
dent manner (Figure 3c). The examination of the p-values
revealed a perturbation of the network even with small
doses and short TNF treatment times. By contrast, while
the biological processes represented in the xenobiotic
metabolism network were clearly activated, following an
expected dose-response pattern, in the smoke-exposed
rat parenchyma (Figure 3b), the companion statistic p-
values indicated that they were not specifically perturbed
in RLAK cells, by any TNF treatment dosage or time
(Figure 3d).
None of the tested method was able to both qualitatively
and quantitatively match the biological expectations for
those use cases, as summarized in Table 4 (and Additional
file 1: Figure S1 and S2). The NPA methodology in [23]
was also applied to the TNF-IL1α-TLR-NFκB network
and shows a slightly inferior behavior (Additional file 1:
Figure S5). Additionally, as the xenobiotic metabolism
network is not causally consistent (e.g., due to the negative
edge from the node taof(AHR) (“transcriptional activation
of nuclear Aryl Hydrocarbon Receptor”) to AHRR (“Aryl
Hydrocarbon Receptor Repressor”), this approachwas not
applicable and further motivated our method that does
not assume causal consistency of the backbone.
In summary, these examples demonstrate that the net-
work perturbation quantifications are able to capture dose
and time dependent response, and that, from a qual-
itative prospective, the developed companion statistics
of the method are able to differentiate perturbed from
non-perturbed biological processes.
Leading nodes provide a mechanistic understanding of the
perturbation
To assess the ability of our approach to elucidate the driv-
ing biological mechanisms in a given network, we applied
our methodology to a transcriptomics dataset reflecting
the entry to S-phase of the cell cycle, which is a well
described mechanism.
Description of the data and networks
Normal Human Bronchial Epithelial (NHBE) cells were
treated with a CDK inhibitor (PD-0332991), thereby
arrested in G1-phase, and then allowed to re-enter the
cell cycle by inhibitor washout. In this experiment, the
re-entry to the cell cycle was confirmed by Fluorescence
Activated Cell Sorting (FACS) analysis of the S-phase
cells at 2, 4, 6, and 8 hours after CDK-inhibitor washout
(Additional file 1: Figure S9a) and showed a time-response
in the increased activity. Transcriptomics data were gener-
ated for all time-points with (INH+GM (growth medium
only)) and without (INH+INH) inhibitor washout
(E-MTAB-1272). We have used our methodology to
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Figure 3 TopoNPA scores and statistics. Panels a) and b): 28-day rat inhalation study, parenchyma tissue. The two network, xenobiotic
metabolism and TNF-IL1a-TLR-NFκB are perturbed across Low, Medium and High dose of cigarette smoke exposure. Panels c) and d): TNF
treatment on RLAK cells. TNF-IL1a-TLR-NFκB network is perturbed in a dose and time dependent manner, while the xenobiotic network is not
perturbed at any dose or time point. Panel e) The TopoNPA scores indicate an increased activation of the cell cycle processes as a function of
recovery time after inhibitor washout (INH+GM vs. INH+INH). The perturbation is significant for all companion statistics at all time points. Panel f)
NPA of the xenobiotic network for the comparisons of former smoker vs. never smoker (left bar) and current smoker vs. never smoker (middle bar) in
GSE7895. The right bar shows the latter comparison in GSE19667. The significance at 0.05 level of the “O” and “K” statistics are indicated by ‘*o’ and
‘k*’. A grey “.o” or “k.”, indicates a P-value between 0.05 and 0.1. The significance with respect to the experimental variation is indicated by a red star
or equivalently can be assessed with the confidence intervals.
analyze network perturbation of the cell cycle network
model, which is a subnetwork of the previously published
cell proliferation model [25] which comprises 127 nodes
and 240 edges (see Additional file 2).
Comparison to other quantification/enrichmentmethods
TopoNPA scores for the appropriate fold-changes
(INH+GM vs. INH+INH for each time point) are shown
in Figure 3e). As expected, the scores reflected a time-
dependent increase in the activation of the cell cycle
following inhibitor washout, matching the increas-
ing pattern from the FACS analysis (Additional file 1:
Figure S9a)). The increase was significant for all compan-
ion statistics at every time points, indicating a specific
perturbation of the network. In Table 4 (and Additional
file 1: Figure S3), we observed that considering the
transcript layer as a gene set and using a Forward FCS
approach was not efficient. This is due to the fact that
more than 8’000 genes are underlying this network
(Table 3). Besides TopoNPA, the backward FCS approach
based on the “fc/maxmean” enrichment statistics matched
the best the expectations. However, it failed to quan-
tify a positive activation of the cell cycle after 2 hours.
The cell cycle model contains many negative feedback
loops, hence is not causally consistent, preventing the use
of [23].
Leading nodes interpretation
While the cell cycle subnetwork encompasses all phases
of the cell cycle, the leading node analysis (Table 5)
were used to identify the key mechanisms that are
relevant for re-entry into S-phase. E2F and its bind-
ing partner TFDP-1 were the most important nodes
in all post-washout time-points that we analyzed, and
the activity of the E2F/TFDP1 complex is essential in



















Table 4 Comparison of the qualitative and quantitative behaviors of the network “perturbation” to the expected behavior in the various datasets and studies
Category Gene-level Enrichment 28-day rat inhalation 28-day rat inhalation RLAK study RLAK study CDKi study Complete match with
statistics statistics TNF-IL1-NFKB xenobiotic TNF-IL1-NFKB Xenobiotic cell cycle biological expectations
Forward FCS
t
mean ×/√ ×/√ √/(√) ./× ×/√ 0
maxmean ×/× (√)/√ ×/× ./× ×/√ 0

























) ./× ×/√ 2
GSEA ×/√ ×/√ ×/(√) ./× ×/√ 0
Backward ORA fdr RCR ×/× √/× ×/× ./√ √/× 1
Backward FCS
t mean ×/× ×/√ ×/× ./√ √/(√) 1
t
maxmean ×/× ×/(√) ×/× ./√ √/× 1























/× √/√ ./√ √/(√) 3

























indicates that the result corresponds to the biological expectation, a (
√
) indicate that up to one exception it matches the expectation, a × indicates that it does not match the expectation, and “.” means that the aspect
is unimportant in the case-study. Finally, “na” indicates that the method does not apply. Each use case is assessed for its quantitative (the first symbol) and its qualitative (second symbol) aspects. The comparison scheme is
discussed in the material and methods and the table is derived from Figures S1-S5. Overall, TopoNPA behaves as expected and is the only method fully matching the expectations.
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Table 5 Rank and direction of change of the leading nodes
for the cell cycle network in the CDKi experiment
2 h 4 h 6 h 8 h
INH+GM INH+GM INH+GM INH+GM
taof(E2F2) 2 (+) 1 (+) 1 (+) 1 (+)
taof(TFDP1) 1 (+) 2 (+) 2 (+) 2 (+)
taof(E2F3) 4 (+) 3 (+) 3 (+) 3 (+)
taof(E2F1) 5 (+) 4 (+) 4 (+) 4 (+)
TFDP1 3 (+) 5 (+) 6 (+) 6 (+)
taof(RB1) 6 (-) 6 (-) 5 (-) 5 (-)
G1/S transition of 7 (+) 7 (+) 7 (+) 8 (+)
mitotic cell cycle
CDC2 8 (+) 8 (+) 9 (+) 9 (+)
THAP1 13 (-) 9 (-) 8 (-) 7 (-)
CDKN1A 12 (-) 10 (-) 10 (-) 10 (-)
E2F2 9 (+) 12 (+) 13 (+) 14 (+)
kaof(CDK2) 15 (+) 11 (+) 11 (+) 12 (+)
kaof(CDC2) 16 (+) 14 (+) 12 (+) 13 (+)
CCNE1 11 (+) 15 (+) 16 (+) 19 (+)
taof(MYC) 18 (+) 16 (+) 15 (+) 15 (+)
CCNA2 10 (+) 13 (+) 17 (+) 25 (+)
taof(FOXM1) 27 (+) 14 (+) 11 (+)
Cell proliferation 19 (+) 19 (+) 18 (+) 18 (+)
kaof(CDK4) 22 (+) 17 (+) 21 (+) 21 (+)
CCNB1 24 (+) 20 (+) 17 (+)
CCNB2 26 (+) 19 (+) 16 (+)
RB1 20 (-) 20 (-) 22 (-) 22 (-)
CDKN1B 21 (-) 18 (-) 25 (-) 24 (-)
CDK4 23 (+) 23 (+) 23 (+)
SKP2 26 (+) 20 (+)
E2F3 14 (+) 21 (+) 27 (+) 31 (+)
CDKN2A 17 (-) 25 (-) 30 (-)
CCND1 22 (+) 24 (+) 26 (+)
kaof(CDK6) 28 (+) 28 (+) 28 (+)








agreement with the literature, several factors known to
favor G1 arrest were leading nodes and were predicted
to have a decreased activity following washout. These
included CDK inhibitors CDKN1A (p21CIP1), CDKN1B
(p27KIP1), and CDKN2A (p16INK4A) [61,62] and the
retinoblastoma protein (Rb) that forms a complex with
E2F, resulting in an inactive or actively repressive complex.
Upon phosphorylation by the CDKs, Rb is released from
E2F, allowing it to drive entry into S-phase [63-65].
In summary, the TopoNPA could identify and quantify
the activation of the cell cycle network upon inhibitor
washout, and capture the essential molecular mechanisms
involved in the G1 to S transition.
TopoNPA-based diagnostic signatures provide
interpretable and robust predictions
To demonstrate how TopoNPA can be employed to derive
robust network signatures, we predicted the smoking sta-
tus of individuals based on the xenobiotic metabolism
network using transcriptomics data from bronchial brush-
ing. As mentioned above, the activation of the xenobiotic
metabolizing machinery is the main immediate cellular
response to combat environmental stressors. In respira-
tory tissue, the activation of this cellular defense system
is highly sensitive and strictly controlled at the transcrip-
tional level by the regulation of the Aryl Hydrocarbon
Receptor (AHR) activity. Therefore, the activation of this
cellular defense system may be a suitable marker to cap-
ture the actual exposure of the target tissue to environ-
mental stressors such as cigarette smoke. The first data set
(GSE7895, [66]) was derived from bronchial brushing of
“current smokers”, “former smokers” and “never smokers”
samples, as described by Beane et al. The second data set
(GSE19667, [67]) was generated from small airway epithe-
lium samples obtained by bronchoscopy from smokers
and non-smokers.
Quantification of the xenobiotic network response
The first step was to compute the TopoNPA scores for
the transcriptomics changes between current smoker and
never smokers to confirm the activation of the xenobiotic
metabolism machinery. For GSE7895, we also compared
former smokers with never smokers. The obtained scores
were clearly elevated for the current smokers in both data
sets (Figure 3f ), while the absolute scores of the two data
sets were unequal. Such differences may be due to short
or long term smoking histories or the distinct cell types
which compose the two samples (large vs. small airways)
[68]. The former smokers comprised in the GSE7895 data
set exhibited a TopoNPA score similar to never smokers
probably because the xenobiotic metabolism is no longer
activated in former smokers as can be easily seen in the
changes in gene expression [66,69].
Interpretation based on the leading nodes
The second step in our process was to identify the leading
xenobiotic metabolism network nodes congruent with the
two data sets.
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Despite the difference in absolute TopoNPA score,
the leading node lists derived from the two datasets
were very similar (Table 6), taof(AHR) (“transcriptional
activation of Aryl Hydrocarbon Receptor”) being the
most highly ranked leading node. Leading nodes such
as Diesel Exhaust Particles, Polycyclic Aromatic Hydro-
carbons (PAH) (also found in cigarette smoke), and
Particulate Matter represent stimuli that initiate signal-
ing cascades similar to those known to be triggered
by cigarette smoke. These include the catalytic activ-
ity (“catof”) of the P450 family enzymes (catof(CYP1B1),
catof(CYP1A1), catof(CYP1A2)) [70] leading to the pro-
duction of Reactive Oxygen Species (ROS) [71] as well as
taof(AHR) [72], all highlighted as leading nodes. Finally,
CYP2E1 activity (oxof(CYP2E1) “oxidase-like activity of
CYP2E1”), also known to be activated by cigarette smok-
ing [70,73], is a leading node. By definition of the leading
nodes, each of these entities are the processes in the back-
bone that are both highly perturbed and central in the
network and altogether explain the network perturbation.
Network-based signature extraction and comparison to
othermethods
We next transformed the individual gene expression data
into network differential backbone values. Extracting the
xenobiotic-relevant biology with the network backbone
enables a supervised mechanism-based separation of the
smoker and never-smokers groups. The comparisons
Table 6 NPA leading nodes of the xenobiotic network for
the comparison current smoker vs. never smoker, all are
positive
Rank GSE7895 GSE19667
1 taof(AHR) (+) taof(AHR) (+)
2 Reactive Oxygen Species (+) Diesel exhaust particles (+)
3 Diesel exhaust particles (+) Reactive Oxygen Species (+)
4 taof(NFE2L2) (+) NFE2L2 (+)
5 NFE2L2 (+) taof(NFE2L2) (+)
6 8-Methyl-IQX (+) 8-Methyl-IQX (+)
7 AHR (+) Polycyclic
Aromatic Hydrocarbons (+)
8 oxof(CYP2E1) (+) catof(CYP1B1) (+)
9 Polycyclic CYP1A1 (+)
Aromatic Hydrocarbons (+)
10 catof(CYP1B1) (+) catof(CYP1A2) (+)
11 catof(CYP1A2) (+) catof(CYP1A1) (+)
12 CYP1A1 (+) Particulate Matter (+)
13 catof(CYP1A1) (+) Soot (+)
14 Soot (+) AHR (+)
15 oxof(CYP2E1) (+)
The nodes also extracted by Nearest Shrunken Centroids are shown in bold.
were performed as described in the method section and
were reported in Table 7. The best performance was
obtained by training Nearest Shrunken Centroids (NSC)
[56] algorithm on the obtained backbone values, by select-
ing the shrinking parameter by cross-validation within
each cross-validation steps. The resulting models led to
very good cross-validation specificity (Sp) and sensitivity
(Se) for both datasets. Importantly, classifying one study
based on the other led to very robust results (GSE7895
predicts GSE19667: Sp=0.87,Se=0.95 and GSE19667
Predicts GSE7895: Sp=0.90, Se=0.94) (Table 7). The best
single UBE classifier was based on the genes under-
lying 8-Methyl-IQX, which was also a leading nodes
(Table 6).
While the cross-validation performances were roughly
similar, methods based on the backbone values led sys-
tematically to higher accuracies on independent datasets
(Table 7).
This showed the ability of network signatures to effi-
ciently handle inter-study bias which is known to greatly
affect gene-based signature predictions. To illustrate the
effect of the transformation to backbone values, princi-
pal component analysis (PCA) was carried out on a) the
full set of genes, b) the set of genes underlying the net-
work and c) the backbone values of each individual in the
study. As can be seen from Additional file 1: Figure S6,
the effect of the smoking phenotype was not the domi-
nant source of variation for the two first cases (panels a
and b), and the direction of separation of the smoking
group averages were strongly disagreeing. In contrast,
the phenotype aligned with the first principal component
(66% of the inertia) in the last case (panel c). This indicated
that the transformation of the gene expression profiles
into differential backbone values matched the smoking
phenotype with the biology encoded in the xenobiotic
metabolism network and potentially reduced the inter-
study bias. Finally, Additional file 1: Figure S6b shows that
this property was not inherent in the gene set defined by
the transcript layer.
The backbone nodes used by Nearest Shrunken Cen-
troids (last line of Table 7) are all leading nodes (Table 6),
with a single exception, “Indirubin”. This shows a strik-
ing coherence between the important nodes in the
network signature and the mechanistic explanation of the
TopoNPA score based on leading nodes.
In summary, TopoNPA ability to establish a quantita-
tive marker for cigarette smoke exposure was verified by
applying the method to datasets from different studies.
It enabled the derivation of a robust network signature
for smoking exposure in the lung, and provided a robust
mechanistic explanation, which showed the coherence of
the TopoNPA framework. Moreover, the method could
extract the meaningful biology from a transcriptomics
data set and classify study participants accordingly by
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Table 7 Prediction sensitivities and specificities for the two datasets, GSE7895 (D1), GSE19667 (D2)
Type Method
CV (D1/D2) D1 → D2 D2 → D1 Mean G-perf
Se Sp Se Sp Se Sp Test sets
All Genes
tForwardLd 0.95/0.86 0.93/0.92 1.00 0.87 0.69 1.00 0.88
NSC 0.92/0.94 0.96/0.93 1.00 0.00 0.98 0.00 0.00
RF 0.75/0.96 1.00/0.97 1.00 0.31 0.98 0.95 0.76
SVM 0.84/0.94 0.98/0.96 1.00 0.00 1.00 0.00 0.00
Gene in transcript layer
tForwardLd 0.95/0.89 0.92/0.93 0.97 0.91 0.61 0.85 0.83
LDA 0.92/0.94 0.80/0.97 0.62 0.27 0.86 0.40 0.50
NSC 0.96/0.92 0.93/0.95 1.00 0.00 1.00 0.00 0.00
RF 0.87/0.96 1.00/0.97 0.98 0.58 0.94 1.00 0.86
SVM 0.88/0.95 0.98/0.95 1.00 0.00 0.78 0.15 0.17
UBE downstream genes
CORG + LDA 0.97/0.94 0.90/0.94 0.83 0.36 0.61 0.55 0.56
CORG + NSC 0.98/0.95 0.93/0.96 0.97 0.00 0.67 0.30 0.22
Best LDA (8-Methyl-IQX) 0.96/0.95 0.88/0.96 0.9 0.80 0.80 1.00 0.89
Best NSC (8-Methyl-IQX) 0.96/0.86 0.92/0.98 0.98 0.76 0.86 1.00 0.90
Backbone values
tForwardLd 0.97/0.90 0.95/0.97 0.8 0.82 0.84 0.90 0.86
LDA 0.96/0.92 0.94/0.98 0.89 0.80 0.84 0.90 0.86
NSC 0.93/0.93 0.81/0.92 0.95 0.87 0.94 0.90 0.91
RF 0.93/0.91 0.80/0.91 0.97 0.73 0.88 0.85 0.85
SVM 0.93/0.93 0.88/0.91 0.98 0.62 0.88 0.90 0.83
The predictions of the samples from the dataset Dj based on the model trained on the dataset Di are reported in the columns Di → Dj . While not systematically
having the best cross-validation performance, the predictors based on the backbone values show are more robust behavior when predicting one dataset based on
the model trained on the other one. The mean of the G-performances (= √Sp · Se) over the two independent test sets are shown in the rightmost column and is
highlighted if > 0.7. The best UBE-based models is chosen based on the mean cross-validation G-performance for the two datasets. The algorithms based on the
backbone values leads systematically to good performances. The cross-validation standard errors are reported in Additional file 1: Table S1.
reducing the importance of the sources of variations irrel-
evant to the biology.
TopoNPA identifies abnormal TLR signaling as a plausible
explanation for poor response to anti-TNFα drug in the
treatment ulcerative colitis
Next we applied TopoNPA to derive a plausible mech-
anistic explanation of the unequal efficacy of an anti-
inflammatory drug in patients suffering from ulcerative
colitis and to generate an accurate and robust network sig-
nature for predicting individual patient responses to the
treatment.
Inflammatory bowel disease
Inflammatory bowel disease (IBD) is regarded as a distur-
bance of immune homeostasis in themammalian intestine
[74]. As evidenced by a number of studies, TNFα plays
a major role in IBD pathology, and TNF-blocking agents
have proven an effective therapy to both ulcerative col-
itis (UC) and Crohn’s disease (CD) [75]. However, the
treatment outcome is highly variable; a monoclonal anti-
body against TNF, Infliximab (IFX), induces remission
in only one third of patients with moderate to severe
UC [76]. To avoid unnecessary adverse drug effects and
needlessly high treatment costs, it is imperative to develop
reliable biomarkers to predict treatment outcome [77].
Gene signatures have emerged as powerful tools to pre-
dict treatment response [78-84]. These include a five-gene
signature that could predict IFX response with high accu-
racy in one cohort, while lacking cross-cohort robust-
ness [79]. The predictive genes were classified as being
involved in the adaptive immune response, yet the bio-
logical pathways that mediate the resistance to therapy
were not identified. To shed more light on the mecha-
nistic reasons behind these IFX responses, we used the
canonical TNF-IL1α-TLR-NFκB network model of NFκB
signaling to capture the network response to measured
gene expression levels. In addition to TNF signaling,
the involvement of both the IL-1 and TLR pathways
are well established in IBD pathology [85-88]; in the
colonic mucosa, TNF, IL1A, and Toll-like receptor sig-
naling all activate NFκB leading to further expression
of inflammatory mediator genes [89]. By applying the
TopoNPA approach to publicly available UC transcrip-
tomics datasets, we set out to predict the treatment
response in two distinct patient cohorts and investi-
gate the biological pathways involved in the treatment
outcome.
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Quantification of network perturbations
We evaluated the transcriptomics profiles of colon sam-
ples (GSE 12251 and 14580) from two cohorts of patients
prior to receiving their first treatment with IFX for refrac-
tory ulcerative colitis [90]. Each patient signature was
compared with the average non-responder signature, and
the network perturbation of the TNF-IL1α-TLR-NFκB
model was used as the input, to find a mechanistic sig-
nature differentiating responders from non-responders.
The scores for the perturbation of the TNF-IL1α-TLR-
NFκB network in IFX responders and non-responders
(for the contrasts “non-responder” vs. “control”, “respon-
der” vs. “control” and “responder” vs. “non-responder” in
the two cohorts together showed the high perturbation
of the network for the non-responder group (Figure 4).
We also used another dataset containing gene expres-
sion profiles of patient colonic biopsies collected pre- and
post-treatment (GSE16879). Overall, the non-responder
network perturbation was already higher than the respon-
der one. This suggests that the quantitative measure of
network perturbation might be indicative of the suscepti-
bility to the treatment.
Interpretation based on the leading nodes
The initial investigation of the leading nodes that defined
the difference between responder and non-responder
patients prior to IFX treatment (Figure 5) highlighted
the involvement of classical TNFR1- mediated signaling
[91]. These nodes were important when comparing all
UC patients with healthy controls and responders to non-
responders. This is in accordance with previous reports
that have demonstrated that TNFα gene expression in
colorectal mucosa and high serum TNF levels can be
used as a predictor for IFX therapy in ulcerative coli-
tis and Crohn’s disease, respectively [92,93]. Interestingly,
MYD88-mediated pathways were also predicted to be
important when comparing the pretreatment data from
responders and non-responders.
Using the dataset containing pre- and post-treatment
effects, we observed that, while MYD88 and TLR (namely
TLR2-, TLR4- and TLR5-related nodes) remain important
nodes to distinguish the non-responders from the respon-
ders even after treatment, IL1R1 signaling was predicted
to be similar in both subject groups (Additional file 1:
Figure S7). Therefore, the underlying biological mecha-
nisms that define the treatment response in UC patients
were possibly related to abnormal TLR signaling and did
not involve directly IL1R1.
Extracting a network-based signature
Standard gene expression-based approaches to predict-

































































































































































































































































































Figure 4 NPA of the TNF-IL1α-TLR-NFκB network in patients with Ulcerative colitis for the comparisons: IFX non-responders vs. control
cases, IFX responders vs. control cases and IFX responders vs. IFX non-responders. The right-hand side of panel b) shows the TopoNPA scores
for the samples collected after IFX treatment (GSE16879), while the other bar plots shows the TopoNPA scores before IFX treatment (GSE 12251 &
GSE14580 (panel a)), GSE16879 (panel b) left-hand side). The significance at the 0.05 level of the “O” and “K” statistics are indicated by ‘*o’ and ‘k*’,
respectively, while the significance with respect to the experimental variation is indicated by a red star.
Martin et al. BMC Bioinformatics 2014, 15:238 Page 18 of 24
http://www.biomedcentral.com/1471-2105/15/238



































































































































































































































































































































































































































































































































































































































































































































Figure 5 Differential network backbone values of TNF-IL1α-TLR-NFκB network for the comparison IFX responders vs. IFX non-responders
from the two cohorts GSE12251 & 14580, showing stronger network perturbation for the IFX non-responder group. Blue shading indicates
a negative value while red shading a positive one. The leading nodes are circled with green. Grey edges represent an activation while black edges
an inhibition. Almost four thousands genes are underlying this network (Table 3).
finding gene signatures (i.e., a short list of genes)
informing the clinicians of the possible response to
the treatment. Arijs et al. reported a small gene sig-
nature using gene filtering and Nearest Shrunken Cen-
troids that suffers from a lack of robustness when using
the gene signature derived from one cohort to pre-
dict the response of a second cohort of patients [90]
(Table 8). The individual patient backbone values of
the TNF-IL1α-TLR-NFκB model were used as the input
for deriving a signature differentiating responders from
non-responders.
Comparisons were performed following the scheme
described in the method section above were reported in
Table 8. NSC combined with the genes underlying a single
UBE and NSC based on the backbone values as the fea-
tures for learning led to the best prediction performances
across cohorts (Table 8). As in the previous example,
performance results showed a more robust behavior of
network-based features as compared to gene selection, for
the majority of the learning algorithms used. Again, this
is in line with the results of the IMPROVER Diagnostic
Gene Signature challenge [53], where it is argued that fea-
tures selection or construction are more important that
the base learning algorithm chosen. The best predictions
based on a single UBE were obtained using the down-
stream genes of catof(TLR2) (“catalytic activity of TLR2”),
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Table 8 Prediction sensitivities and specificities for the two cohorts, A and B
Type Method
CV (A/B) A → B B → A Mean G-perf
Se Sp Se Sp Se Sp Test sets
All Genes
tForwardLd 0.38/0.63 0.80/0.65 0.50 0.82 1.00 0.88 0.79
From Arijs, 2009 Accuracy: 0.92/0.91 0.25 1 Accuracy: 0.71 na
RF 0.20/0.82 0.88/0.73 0.25 0.91 0.62 0.75 0.58
SVM 0.52/0.78 0.85/0.69 0.42 0.82 0.62 0.75 0.63
NSC 0.48/0.78 0.80/0.58 0.67 1.00 0.69 0.88 0.80
Gene in transcript layer
tForwardLd 0.50/0.68 0.83/0.62 0.67 1.00 0.88 0.69 0.80
LDA 0.43/0.90 0.84/0.65 0.42 0.82 0.88 0.62 0.66
NSC 0.60/0.88 0.79/0.58 0.75 0.73 0.88 0.56 0.72
RF 0.28/0.85 0.88/0.71 0.33 0.82 0.88 0.69 0.65
SVM 0.52/0.77 0.86/0.69 0.42 0.82 0.88 0.69 0.68
UBE downstream genes
CORG + LDA 0.33/0.73 0.68/0.62 0.25 0.64 0.75 0.69 0.56
CORG + NSC 0.62/0.90 0.78/0.60 0.50 0.82 0.88 0.69 0.71
Best LDA (MAP3K1) 0.45/0.98 0.78/0.69 0.58 0.91 1.00 0.75 0.80
Best NSC (catof(TLR2)) 0.85/0.92 0.80/0.56 0.75 1.00 1.00 0.69 0.85
Backbone values
tForwardLd 0.53/0.82 0.75/0.75 0.50 0.64 1.00 0.62 0.68
LDA 0.75/0.75 0.76/0.75 0.50 0.73 0.88 0.56 0.65
NSC 0.98/0.98 0.75/0.67 0.92 0.82 1.00 0.62 0.83
SVM 0.78/0.78 0.40/0.77 0.91 0.50 0.69 0.88 0.73
RF 0.75/0.82 0.62/0.78 0.82 0.75 0.75 0.88 0.80
The predictions of the samples from the cohort A (B respectively) based on the model trained on the cohorts B (A respectively) are reported in the columns A → B
(B → A respectively). The mean of the G-performances (= √Sp · Se) over the two independent test sets are shown in the rightmost column and is highlighted if > 0.7.
The best UBE-based models is chosen based on the mean cross-validation G-performance for the two datasets. The algorithms based on the backbone values leads to
good performances for a majority of algorithms. The cross-validation standard errors are reported in Additional file 1: Table S2.
which is one of the leading nodes (Figure 5) and is involved
in the TLR-signaling.
As observed in the previous use-case, the inter-study
robustness might be explained by the alignment of the
responsiveness status with the first principal compo-
nent (94.7% of the total variance) of the individual
backbone values; as opposed to the behavior of the
principal components based on the gene expression data
(Additional file 1: Figure S8).
Discussion
We have presented several biological and clinical appli-
cations of TopoNPA, a novel quantitative approach that
uses knowledge-based cause-and-effect biological net-
work models describing complex processes involving
thousands of genes. As an input TopoNPA requires high-
throughput transcriptomics data obtained from appro-
priately designed and executed studies, and a network
model relevant to the observed biological response. Our
method provides a coherent mechanism-based frame-
work for assessing and quantifying the resulting pertur-
bations of the network as required in a dose-response
toxicity setting. It also guides mechanistic interpretation
at node-level resolution in a fully coherent way with
the perturbation itself. The relevance of the mechanis-
tic interpretation of the network perturbation has been
demonstrated in two controlled in vitro studies (CDKi and
TNF experiments), and applied to two in vivo studies. In
addition to the quantification of the perturbation and its
interpretation, our framework enables the establishment
of coherent, efficient and robust diagnostic classifiers
based on individual sample network perturbations. We
have shown how to use the established biology of xenobi-
oticmetabolism to stratify a human cohort of smokers and
non-smokers. The full potential of this powerful approach
for deriving mechanism-based interpretation and diagno-
sis has been further demonstrated in the context of an
in-vivo study of ulcerative colitis patients, where a testable
hypothesis has been proposed regarding the individual
response to the drug Infliximab (see below).
Network perturbation amplitudemethodology
Overall, the TopoNPA approach belongs to the class of
backward PT methods (Table 1), and is threshold-free
because it does not require any filtering of the gene
expression data based on expression value or statistical
Martin et al. BMC Bioinformatics 2014, 15:238 Page 20 of 24
http://www.biomedcentral.com/1471-2105/15/238
significance. In our method, the absence of any fold-
change between conditions can be as informative as high
fold-changes. It provides a single framework for quan-
titative and qualitative evaluation of the amplitude of
perturbation of a network.
It applies to two-layer cause-and-effect models without
any assumption beyond the underlying undirected graph
to be strongly connected. In contrast to the approach
in [23], the quantification of network perturbations as a
positive-definite quantity (quadratic in the β) allows for
causal inconsistency, does not require the choice of a ref-
erence node, uses fully the topology of the network and
avoids canceling out “destructive interference” in cumu-
lative signed amplitudes (for example when half of the
network is positive, and half is negative). Our choice was
to consider an “energy” analogue quantity (Figure 1c, top
panel) rather that a signed value as used byMartin et al. As
a particular case, if the functional layer was made of a sin-
gle node (with a self-loop), then the backbone differential
value of that node would equal the NPA score in [23].
TopoNPA enables the quantification of the network
response to a treatment, which is a key feature in sys-
tems toxicology. Attempts to adapt existing gene set-
based methods cannot exploit fully the two-layer network
structure as either the quantification or the qualitative
assessment of the perturbations computed in the dif-
ferent studies did not match the biological expectations
(Table 4).
Our framework offers the possibility to identify key con-
tributors of the perturbation in the network using the
leading nodes (Figure 1c, middle panel), which have been
shown to be pertinent in the positive control experiment
(CDKi experiment). This aspect is not covered in our pre-
vious methodology [23] as the network was aggregated
in a single UBE structure and subsequently scored. An
even deeper investigation is possible by defining a simi-
lar notion of leading genes for any (leading) node in the
network. However, we believe that the gene expression
is the consequence and not the driver for the biological
processes of the network, and therefore this was not be
systematically looked at. Furthermore, the modern view
of network biology implies that the essence of biological
processes does not lie in the individual behavior of genes,
but rather in their collective action, which is precisely
captured by the biological network models [4,41,94].
Network-based Signatures: constructing vs. extracting
features
We have shown in two cases that our approach has led
to accurate and, importantly, robust classification of indi-
vidual samples. Even if our goal was not to develop a
purely machine-learning algorithm, it clearly appeared
that an appropriate choice of the network model led to
remarkable performances in classification tasks that is
over-performing other approaches and the results pub-
lished by the authors of the original studies. TopoNPA
enabled to build network features that leads to more
robust classification results, almost independently of the
learningmethodology used. The key aspect for this behav-
ior is that gene expression profiles are used to construct
(as opposed to extract) new features in a surjective way
by a data independent linear mapping (Figure 1c, bottom
panel). As the dimension of the backbone is far lower than
the dimension of the underlying gene space, it is expected
that our network signatures will be robust. Additionally
if the phenotype of interest is associated with the biol-
ogy encoded in the functional layer of the network, the
class separation is expected to align with the main varia-
tion of the differential backbone values. This behavior is
apparent in the PCAs constructed on the backbone values:
the inter-class variability is aligning with the main direc-
tion of variation. Additionally, the transformation seems
to reduce the inter-study bias. Another benefit of this lin-
ear transformation is to move away from the so-called
“p >> n problem”, where there are far more variables
than samples in a dataset and hence lead to more robust
diagnoses. Gene-sets or network have also been leveraged
in classification problems based on gene-expression data
[33-35]. However the enrichment of a given gene-set and
its ability to provide discriminant score rely usually on
independent algorithms. Also, this aspect is not covered
in our previous methodology [23].
This application revealed a promising potential for our
approach in the context of personalized medicine: per-
sonalized diagnosis based on the classifier to decide the
administration of the Infliximab treatment. Also, the
smoking network signature derived could serve as an
individual marker of smoking exposure in a clinical trial.
Network-based biological explanation and hypothesis
generation
The analysis of UC patient data from responder and non-
responder subjects prompted the generation of a network-
level hypothesis. Based on our analysis, TNFR1A-
signaling seems to be an important node in defining the
difference between the responders and non-responders
before and after anti-TNF treatment. This suggests that
the treatment fails to fully restore normal TNF signal-
ing in the colonic mucosa of non-responders. However,
a recent study has shown that TNF-expression returned
to normal at week 30 in both IFX responders and non-
responders [95]. Therefore, the stimulated TNF signaling
is not the only explanation for poor treatment outcome
in non-responders. Our results indicate that the under-
lying biological mechanisms that define the treatment
response to TNF blocking agents in UC patients might
be related to abnormal MYD88-signaling. MYD88 has
been found to be involved in IBD pathology [96,97] and
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the involvement of MYD88 in response to TNF-blocking
drugs has been demonstrated in studies on rheuma-
toid arthritis (RA) patients [98]. Our analyses further
showed that MYD88 and TLR (namely TLR2-, TLR4- and
TLR5-related nodes) remained important nodes to dis-
tinguish the non-responders from the responders even
after treatment. A recent study by Toedter et al. showed
that the genes involved in intestinal epithelial barrier
defense were differentially expressed in the responder and
non-responder colonic mucosa following Infliximab ther-
apy [95]. Members of the TLR family are involved in
the injury of the intestinal epithelial barrier, and their
abnormal function could lead to defects in mucosal bar-
rier defense in the non-responder population [99,100].
The identification of a high frequency of peripheral T-
regulatory cells as a predictive marker for Infliximab
treatment response provides additional support for the
involvement of abnormal TLR signaling [101-103]. Trip-
tolide, an active component isolated from the Chinese
herb Tripterygium wilfordii with anti-inflammatory and
immunosuppressive properties, has been proposed as an
alternative compound for the treatment of CD. Interest-
ingly, the favorable effect was shown to be mediated by
targeted inhibition of TLR2/TLR4 signaling in the IL10-
/- CD mouse model, and in cultured colon tissue samples
from CD patients [97]. Finally, Gewirtz et al., discov-
ered that patients from a specific ethnic background with
deficient TLR5 were protected from developing CD, advo-
cating the pharmacological inhibition of the TLRs as an
alternative to anti-TNF compounds to treat IBD [104].
Such an approach has already been applied for the treat-
ment of RA, where TLR2/TLR4 antagonists have proven
beneficial in treating an autoimmune disorder [105].
On-going research in our group is currently using sev-
eral network models in conjunction first, to develop
methods of assessing the biological impact of individual
substances, or a set of substances on a biological system,
as we have discussed in [41] and second to improve the
performance of the backbone-based classifiers.
Conclusion
Themethodology proposed in this study provides a coher-
ent framework going beyond the work of [23] (Table 1,
last two rows) to handle the two-layered structure of
cause-and-effect networks (Figure 1a). Firstly, it quantifies
network perturbations using differential gene expression
in conjunction with the explicit network topology and
tests a non-perturbation null hypothesis (Figure 2); hence
it positions itself as a backward-based PT methodology
(Table 1). Secondly, our methodology calculates the per-
turbation of the network by inferring differential values for
each node of the functional layer of the network model,
referred to as differential backbone values. Those quanti-
ties facilitate the biological interpretation by decomposing
the amplitude of the perturbation and thereby identifying
candidate key nodes of the functional layer. Thirdly, it fur-
ther enables the calculation of these differential backbone
values at sample level, which serves to build a knowledge-
driven classification of individual patients. Such classify-
ing signatures, which benefit from the mechanistic inter-
pretation of the differential backbone values, can be used
to classify individual patient samples. To the best of our
knowledge this is the first approach that provides, in a sys-
tematic manner, the ability to fully exploit the information
provided in two-layer causal models (i.e. using explicitly
the full signed network topology), that serves simultane-
ously for quantitative perturbation assessment, biological
interpretation and diagnostic signature extraction. Here
we show that using our biological network models to
quantify individual patient responses through a network
model relevant to the phenotype of interest is a biologi-
cally meaningful, interpretable, robust and effective way
of deriving network-based signatures.
As a summary, a novel network-based methodology for
quantifying perturbation, interpreting data and for deriv-
ing network signature was presented. It fully exploits the
specific structure of two-layer cause-and-effect network
models, made of a functional layer and a transcript layer.
The application of our methodology has provided insight
into molecular mechanisms by capturing the perturbed
network components with high specificity, and has led to
robust signatures for diagnosis. The successful applica-
tion of our quantitative method has clearly demonstrated
the potential of TopoNPA in systems biology and systems
toxicology.
Endnote
a l2(A) = { f : A → R|∑a∈A f (a)2 < ∞} which, for a
finite set A, is isomorphic to RN , where N is the
cardinality of A.
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